Navigation Links
BIND Biosciences To Install First Siemens Simatic(R) PCS 7 Lab Process Control System in the U.S.
Date:3/17/2009

ATLANTA, March 17 /PRNewswire/ -- Siemens Energy & Automation, Inc. announced today that BIND Biosciences, Inc., Cambridge, Mass., has selected Simatic(R) PCS 7 Lab hardware and software to help its scientists manage pre- and post-clinical experimental data.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

BIND Biosciences develops targeted therapeutics based upon their novel polymeric nanoparticle drug delivery technology platform. It is the first company in the United States to install the PCS 7 Lab hardware and software.

With startup services provided by system integrator Optimation Technology, Inc., the phased automation implementation will help BIND Biosciences drive process development as well as monitor and control manufacturing operations.

"The flexibility and expandability of the PCS 7 Lab system will allow us to grow economically and efficiently through all three phases of the implementation," said Jeff Hrkach, BIND Biosciences Vice President of Pharmaceutical Sciences. "The system has all the tools we need to collect and manage our data as well as protect our intellectual property."

The PCS 7 Lab configuration, designed for laboratory and process development research and development applications, is based on Siemens Simatic PCS 7 Box. The UL certified system includes a preinstalled rack of I/O modules that can be easily reconfigured to fit any size or type of laboratory environment.

"This partnership with BIND gives Siemens the opportunity to help BIND bring drugs to market faster, " said Glenn Restivo, Siemens Life Sciences Industry Manager. "We adhere to the Design of Experiment and Quality by Design philosophies that build quality into every step of the process - from laboratory experimentation through every phase of manufacturing."

The implementation phase of the PCS 7 project is underway and focuses on basic experimentation and data collection. A second phase is under consideration for cataloging and organizing experimental data. Phase three, also under consideration, will include Siemens Sipat for Process Analytical Technology (PAT), Interspec for specification management and the R&D Suite for Electronic Lab Notebook (ELN).

About Siemens:

Siemens Energy & Automation, Inc. is one of Siemens' operating companies in the U.S. Headquartered in the Atlanta suburb of Alpharetta, Ga., Siemens Energy & Automation, Inc. manufactures and markets one of the world's broadest ranges of electrical and electronic products, systems and services to industrial and construction market customers. Its technologies range from circuit protection and energy management systems to process control, industrial software and totally integrated automation solutions. The company also has expertise in systems integration, technical services and turnkey industrial systems. For more information: www.sea.siemens.com.

Siemens AG (NYSE: SI) is a global powerhouse in electronics and electrical engineering, and operates in the industry, energy and healthcare sectors. For more than 160 years, Siemens has built a reputation for leading-edge innovation and the quality of its products, services and solutions. With 428,000 employees in 190 countries, Siemens reported worldwide sales of $116.6 billion in fiscal 2008. With its U.S. corporate headquarters in New York City, Siemens in the USA reported sales of $22.4 billion and employs approximately 69,000 people throughout all 50 states and Puerto Rico. For more information on Siemens in the United States, visit www.usa.siemens.com.


'/>"/>
SOURCE Siemens Energy & Automation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
3. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
4. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
5. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
6. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
7. Anaptys Biosciences Raises Over $33 Million in Series B Financing
8. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
9. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
11. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... New Jersey (PRWEB) , ... March 23, 2017 ... ... developer of herbal-based and non-steroidal skincare products, was awarded as winners of American ... innovation products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... 23, 2017 , ... The Boulevard is honored to host Shriners and Masons ... be located in the Main West Entrance of The Boulevard (in front of JCPenney). ... is necessary and each child with a parent or guardian will be photographed for ...
(Date:3/23/2017)... ... ... “Beyond and Back”: a true-life testimony of tragedy and the miraculous power ... Rose, a wife, mother and grandmother committed to sharing her many spiritual adventures which ... new book presents actual events in the life of her family, which validate her ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... ... has selected HealthiPASS, an innovative patient - centric payment system, to expand its ... massive improvements in the patient financial experience. , “At Ogden Clinic, we ...
(Date:3/23/2017)... ... March 23, 2017 , ... “More Corruption”: a simple and strong explanation of the God’s ... the rulers of Heaven was asked by God to write a book about Him. , ... just because I kept my commitment to the Lord God. They have not walked in ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... , Mar 23, 2017 NeuroVive Pharmaceutical ... today announced that the English version of the Annual report ... www.neurovive.com .  ... About NeuroVive NeuroVive Pharmaceutical AB is a ... discovery and development of medicines that preserve mitochondrial integrity and ...
(Date:3/22/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Respiratory care ... 10.9% over the next decade to reach approximately $38.27 billion by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... Under the impetus of the fast-growing ... increased year by year at the CAGR of ... market size will maintain the growth rate of ... billion in 2021, thanks to severe aging, the ... agents and supporting policies. At present, Chinese ...
Breaking Medicine Technology: